Highlights Vivos Inc.

Equities

RDGL

US92858K2042

Market Closed - OTC Markets Other stock markets 15:59:52 2024-06-07 EDT			5-day change	1st Jan Change
0.1732 ^USD	-1.00%		-0.69%	+139.70%

05-09	Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-18	Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Vivos Inc. Announces Radiogel(TM) Precision Radionuclide Therapy(TM) Receives FDA Breakthrough Device Designation	12-20	CI
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Vivos Inc Files A New Patent on Alternate Particles for Precision Radionuclide Therapy	23-01-11	CI
Vivos Inc. Files New Patent on Precision Radionuclide Therapy Support System Equipment	23-01-03	CI
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-19	CI
Vivos Inc. Files A New Patent on the Hydrogel Component of Isopet®/Radiogel™	22-09-14	CI
Vivos Inc. Announces a New IsoPet® Precision Radionuclide Therapy Regional Clinic for Equine Therapy	22-08-16	CI
Vivos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-25	CI
Vivos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-07	CI
Vivos Inc. Files Its Particle Patent in Several Countries	22-02-24	CI
Vivos Inc. Obtains Feedback from the FDA on Clinical Testing of RadioGel?	21-12-02	CI
Vivos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-25	CI
Vivos Inc Signs A Memorandum of Understanding for A New Regional Clinic in Ny for Isopet Therapy	21-10-18	CI
Vivos Inc. Files Early Feasibility IDE Application with FDA for Radiogel™	21-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vivos Inc.

Equities

RDGL

US92858K2042

Highlights

Filters